Cantor Fitzgerald Forecasts CLDX FY2025 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of ($3.61) for the year. Cantor Fitzgerald has a “Overweight” rating and a $67.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Several other equities research analysts also recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Citigroup began coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Finally, Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $24.24 on Wednesday. The company has a 50-day moving average of $25.70 and a two-hundred day moving average of $31.68. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -9.43 and a beta of 1.62. Celldex Therapeutics has a one year low of $22.17 and a one year high of $53.18.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $26.82 per share, with a total value of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP increased its position in Celldex Therapeutics by 14.5% during the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after buying an additional 1,167,659 shares during the last quarter. Novo Holdings A S bought a new stake in shares of Celldex Therapeutics during the 2nd quarter worth about $31,458,000. Point72 Asset Management L.P. increased its holdings in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after acquiring an additional 654,194 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after acquiring an additional 479,068 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after purchasing an additional 321,325 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.